Abstract
Background
Circular RNAs (circRNAs) play various roles in the development of many autoimmune diseases. However, their expression profiles and specific function in Sjögren's Syndrome remains largely unknown.
Objectives
We aimed to investigate circRNAs potential diagnostic value in primary Sjögren's syndrome (pSS) and contribution to the pathogenesis of pSS.
Methods
This study included 102 subjects, 51 pSS patients and 51 healthy controls. The concentration of hsa_circ_0045800 was analyzed in peripheral blood mononuclear cells obtained from 51 pSS patients and 51 healthy controls by qRT-PCR. We established a receiver operating characteristic curve (ROC) to assess the biological diagnostic value of hsa_circ_0045800 for pSS. In addition, we analyzed the correlation between hsa_circ_0045800 and disease activity in Sjogren's syndrome. A differential analysis was also conducted on the concentration of hsa_circ_0045800 in patients in pSS patients before and after treatment. We studied the downstream mechanism of hsa_circ_0045800 through bioinformatics analysis and confirmed it using luciferase reporter gene assay.
Results
We confirmed that the concentration of hsa_circ_0045800 was elevated 10.4-fold in peripheral blood mononuclear cells of pSS patients than in healthy controls (p = 0.00). In the pSS active disease group, the concentration of hsa_circ_0045800 is 2.5-fold higher compared to the pSS non-active disease group (p = 0.04). The concentration of hsa_circ_0045800 after treatment was decreased by 80% compared with that before treatment (p = 0.037), suggesting its utility as a potential marker for monitoring treatment efficacy. ROC curve analysis showed that the diagnostic value of hsa_circ_0045800 in pSS patients was significantly higher than that in healthy controls, with an area under the curve of 0.865, a sensitivity of 74%, and a specificity of 92%. The concentration of hsa_circ_0045800 is correlated with various clinical factors: the concentration of hsa_circ_0045800 is positively associated with age (r = 0.328, P = 0.019), oral dryness (r = 0.331, P = 0.017), while it is negatively correlated with HGB (r = -0.435, P = 0.001) and and hypothyroidism (r = -0.318, P = 0.023). Bioinformatics predictions and luciferase assays indicated that hsa_circ_0045800 acts as a molecular sponge for miR-1247-5p, with SMAD2 being a target gene of miR-1247-5p.
Conclusion
Our study results show that hsa_circ_0045800 potentially contributes to the development and progression of pSS via the miR-1247-5p/SMAD2 pathway. Peripheral blood mononuclear cells are directly involved in the pathogenesis of pSS, and the discovery of hsa_circ_0045800 in peripheral blood mononuclear cells highlights its potential as a novel biomarker for disease activity and diagnosis in patients with pSS.
|
Key Points • The concentration of hsa_circ_0045800 was higher in peripheral blood mononuclear cells of pSS patients. • Hsa_circ_0045800 promoted pSS progression through miR-1247-5p–SMAD2 axis. • Hsa_circ_0045800 is a potential biomarker for pSS. |
Supplementary Information
The online version contains supplementary material available at 10.1007/s10067-024-06999-0.
Keywords: Hsa_circ_0045800, miR-1247-5p, Primary Sjögren’s syndrome, SMAD2
Introduction
Primary Sjogren's syndrome (pSS) is a chronic autoimmune disease that invades exocrine glands and lymphocyte proliferation. It is characterized by dry eyes and mouth caused by lacrimal gland and salivary gland dysfunction [1–3], which mainly affects middle-aged women, with a male-to-female ratio of 1: 9 [4, 5]. At present, the pathogenesis of pSS is unknown, and many factors such as heredity, infection and environment are involved in the pathogenesis [6]. In recent years, people have been trying to find reliable biomarkers to improve the diagnosis algorithm and new treatment scheme of pSS patients.
CircRNA is a newly discovered single-stranded circRNA molecule, which is formed by the reverse shear of the downstream sequence of the precursor mRNA (the 3' end) and the upstream RNA sequence (the 5' end) to form a special ring structure. CircRNA has neither 5' to 3' polarity nor a polyadenylation tail, so it is not easy to be degraded by exonucliase [7]. At present, circRNA has been found to have various types, rich content, long half-life and good stability [8, 9]. Recent studies have shown that its cis-regulation of parent genes [7], sponge miRNA [10], binding to proteins and forming functional complexes [11], translation proteins [12] and other roles play key roles in eukaryotic cells. Studies have been conducted on the relationship between circRNA and various diseases, such as tumor, cardiovascular disease, nervous system disease, autoimmune disease, etc. [13–16]. Therefore, circRNA can be used as a biomarker as a potentially valuable diagnostic tool for pSS disease. There are few studies on the role of circRNA in the pathogenesis of pSS.
In our previous research, We have explored the clinical correlation of circRNA and pSS and found that the expression of hsa_circ_0045800 in peripheral blood of patients with pSS was significantly increased by screening with high-throughput gene chip [17]. It may be used as a diagnostic marker for pSS. In this study, a novel circRNA, hsa_circ_0045800, was identified in peripheral blood mononuclear cells, that was associated positively with pSS disease activity. Hsa_circ_0045800 exhibited notable specificity and sensitivity, suggesting strong potential as a diagnostic biomarker for pSS. Furthermore, we explored that hsa_circ_0045800 could act as a sponge for hsa-miR-1247-5p to regulate SMAD2 expression in the progression of pSS.
Methods
Participant information
This study involved 51 pSS patients admitted to the Department of Rheumatology at the General Hospital of Ningxia Medical University between June 2018 and June 2021. These patients were diagnosed with primary Sjögren's syndrome (pSS) based on the 2002 American-European Consensus Group (AECG) standards combined with the 2016 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification criteria [18]. All patients had complete case data and had signed informed consent forms.
The exclusion criteria for the case group included: not meeting the diagnostic criteria for primary Sjögren's syndrome (pSS), the coexistence of other autoimmune diseases, the presence of head, neck tumors, and lymphomas, concomitant hematologic disorders (considering pSS can involve the hematologic system), recent severe infections (indicated by elevated inflammatory factors), severe cardiac or hepatic failure (evidenced by abnormal liver and kidney functions), and recent use of cholinergic drugs (which can cause symptoms of dry mouth).The control group comprised 51 healthy individuals who underwent medical examinations at the General Hospital of Ningxia Medical University during the same period. The inclusion criteria for the control group were: not meeting the diagnostic criteria for primary Sjögren's syndrome (pSS), no personal or immediate family history of autoimmune diseases, no use of steroids, immunosuppressants, or similar medications including cyclophosphamide, methotrexate, leflunomide, azathioprine, and cyclosporine in the past three months, and being free from infections, tumors, and communicable diseases.
The study received approval from the Ethics Committee of the General Hospital of Ningxia Medical University [2018–099, 2020–313], and all participating researchers had signed informed consent forms.
Specimen collection and RNA isolation
The peripheral blood (5 ml) of the participants was collected by EDTA anticoagulation vacuum tube, and the blood was stored in a specimen storage box at 4℃. Within 4 h after collection of peripheral blood samples, peripheral blood mononuclear cells were isolated from pSS patients and healthy controls using human peripheral blood lymphocyte separation medium (Biyuntian, China). Total RNA was extracted by Batek RNA extraction kit RP4002 according to the in Total RNA was extracted by Batek RNA extraction kit RP4002 according to the instructions, and RNA concentration and purity were measured by Nanodrop2000( Thermo Scientific, USA). The isolated total RNA was stored at-80 C or immediately used for reverse transcription.
Real-time quantitative reverse transcription PCR (qRT-PCR)
The prepared total RNA was reverse transcribed by Primescript RT kit (Takara Bio, Japan) according to the product specification to obtain total cDNA, which was used as template and β-actin gene as internal reference. Using the Lightcycler 480 System, the reaction conditions were kept at 95℃ for 3 s, and the amplification was carried out after 40 cycles of denaturation at 95℃ for 5 min and denaturation at 60℃ for 30 s. The experimental results showed that the difference of CT value (the number of fractional cycles of fluorescence exceeding a given national value) was less than 0.5, and the concentration of circ_0045800 was analyzed by 2−△△Ct method, and the experiment was repeated three times. Primers used in this study were hsa_circ_0045800 upstream primer 5'-TTTACTTGCAGTGAAGCGCC-3', downstream primer 5'-GCTTCGCTCTTGGTTTTGGA-3', and reference β-actin upstream primer 5 '-CCACGGCTGCTTCCAGCTCC-3', downstream primer 5 '-GGACTCCATGCCCAGGAAGGAA-3'.
Cell transfection
The miR-1247-5p mimics were designed by HanYi Biosciences lnc (Guangzhou, China) NC for mimics used as a corresponding negative control. Additionally, the luciferase reporter plasmids, which included both the wild-type and mutant sequences of hsa_circ_0045800 and the SMAD2 3′-UTR were supplied by HanYi Biosciences lnc (Guangzhou, China). These plasmids, together with the miRNA mimics, were transfected into HEK293T cells using the transfection agent Lipofectamine 2000, provided by Invitrogen in the USA. Following a 24–48 h incubation period post-transfection, the cells were harvested for further experimental analysis. The mimics sequences for miR-1247-5p are listed below: ACCCGUCCCGUUCGUCCCCGGA.
Dual-luciferase reporter assay
We used luciferase reporter gene method to identify the binding of selected RNA molecules. The luciferase reporter plasmids of wild sequence hsa_circ_0045800, SMAD2 3 ′-UTR and mutant sequence hsa_circ_0045800, SMAD2 3 ′-UTR were constructed. Subsequently, 2 × 105 HEK293T cells were inoculated into a 24-well plate and co-transfected with a mixture of 1 μg luciferase reporter plasmids and miRNA mimics. After incubation for 48 h, the activities of luciferase and reninase were quantitatively determined by double luciferase detection system. Detection system (Promega, Madison, USA).
Statistical analysis
Statistical analysis was performed using GraphPad Prism v5.0 software (GraphPad software, Inc.) and SPSS 25.0 software (SPSS, Inc. to analyze circRNAs expression differences between the two groups using Student's t test or nonparametric Mann–Whitney test. Wilcoxon rank sum test was used for paired samples. Spearman rank correlation analysis was used to analyze the correlation among parameters. The diagnostic value of circRNAs was evaluated by receiver operating characteristic (ROC) curve. P < 0.05 was considered to be statistically significant.
Results
The characteristics of the study population
In this study, we collected 51 patients with pSS including 47 females and 4 males, aged from 21 to 77 years old, and 51 healthy controls including 42 females and 9 males, aged from 20 to 68 years old. There was no significant difference in age or sex between pSS patients and healthy controls (Table 1).
Table 1.
General data analysis of this study population
| pSS patient | Healthy control | t/2 value | P value | |
|---|---|---|---|---|
| Age (years) | 49.9 ± 13.73 | 46.0 ± 11.99 | 1.068 | 0.288 |
| Sex(male/female) | 4/47 | 9/42 | 2.210 | 0.137 |
There was no significant difference in age or sex between the pSS patients and healthy controls
Identification of hsa_circ_0045800 concentration difference in peripheral blood mononuclear cells between pSS patients and control controls.
The concentration of hsa_circ_0045800 in peripheral blood mononuclear cells of pSS patients was higher 10.4-fold than in the healthy controls (p = 0.000) (Fig. 1, Supplement Table 1).
Fig. 1.
The concentration of hsa_circ_0045800 in pSS patients and healthy controls. By determining the concentration of hsa_circ_0045800, we found that hsa_circ_0008301 expression concentration was increased in patients with pSS when compared with healthy controls(P < 0.05)
Potential biological value of hsa_circ_0045800 in patients with pSS.
ROC curve analysis results for hsa_circ_0045800 showed that the ROC curve area (AUC) was 0.865 (95%CI = 0.791–0.940, P < 0.05), the sensitivity was 74%, and the specificity was 92% (Fig. 2).
Fig. 2.
The ROC curve assessing the diagnostic potential of hsa_circ_0045800 concentration for pSS. The ROC curve analysis on the concentration of hsa_circ_0045800 in pSS patients and the health controls that hsa_circ_0045800 has high diagnostic efficiency in pSS patients
Differential concentration of hsa_circ_0045800 in patients with pSS.
We compared the concentration of hsa_circ_0045800 in different gender, age and course of disease in pSS patients. Hsa_circ_0045800 concentration was higher 2.6-fold in patients aged 50 years and above than in patients aged less than 50 years (p = 0.032) (Table 2, Supplement Table 1). There was no significant difference in the concentration of hsa_circ_004580 between the sexes and the course of disease (Table 2).
Table 2.
Comparison of hsa_circ_0045800 concentration in different gender, age, ESSDAI, treatment and course of disease in pSS patients
| n | hsa_circ_0045800 M(P25,P75) |
Z value | P value | |
|---|---|---|---|---|
| Sex | -1.051 | 0.314 | ||
| female | 47 | 0.077 (0.036, 0.190) | ||
| male | 4 | 0.057 (0.029, 0.076) | ||
| Age (years) | -2.149 | 0.032* | ||
| ≥ 50 | 22 | 0.103 (0.066, 0.266) | ||
| < 50 | 29 | 0.063 (0.026, 0.107) | ||
| Disease duration(years) | -0.321 | 0.748 | ||
| ≥ 10 | 11 | 0.097 (0.019, 0.190) | ||
| < 10 | 40 | 0.074 (0.038, 0.166) | ||
| ESSDAI | -2.053 | 0.016* | ||
| ≥ 5 | 43 | 0.088 (0.052, 0.185) | ||
| < 5 | 8 | 0.029 (0.009, 0.066) | ||
| Untreated | -2.075 | 0.037* | ||
| Yes | 15 | 0.080 (0.040, 0.255) | ||
| No | 15 | 0.034 (0.010, 0.105) |
The difference in the concentration of hsa_circ_0045800 among PSS patients aged 50 or above, with ESSDAI greater than or equal to 5, and whether they received treatment, has statistical significance
Subsequently, the concentration of hsa_circ_0045800 with different clinical manifestations were compared in pSS patients. The concentration of hsa_circ_0045800 was higher 4.7-fold in patients with oral dryness symptoms than in patients without oral dryness symptoms (P = 0.016). (Fig. 3A, Supplement Table 1). However, the concentration of hsa_circ_0045800 showed no statistical significance in the presence or absence of ocular dryness, tooth damage, dry skin, fatigue, purpura, joint pain, lymph node enlargement, Raynaud's phenomenon, and morning stiffness (Fig. 3A, Supplement Table 2).
Fig. 3.
The concentration of hsa_circ_0045800 in pSS patients is different. A, The concentration of hsa_circ_0045800 was varied in clinical manifestations. 1 Oral dryness (Yes: n = 46 No: n = 5), 2 Ocular dryness (Yes: n = 35 No: n = 16), 3 Dental damage (Yes: n = 19 No: n = 32), 4 Skin dryness (Yes: n = 8 No: n = 43), 5 Fatigue (Yes: n17 No: n = 34), 6 Skin purpura (Yes: n = 7 No: n = 44), 7 Joint pain (Yes: n = 7 No: n = 44), 8 Lymph node enlargement (Yes: n = 7 No: n = 44), 9 Raynaud's phenomenon (Yes: n = 7 No: n = 44), 10 Morning stiffness (Yes: n = 11 No: n = 40). * indicates P < 0.05, which is statistically significant. B, The concentration of hsa_circ_0045800 were differ from laboratory indexes in pSS patients. 1. WBC < 3.5 * 10 ^ 9 / L (Yes: n = 36 No: n = 15), 2. NEUT < 1.5 * 10 ^ 9 / L (Yes: n = 41 No: n = 10), 3. LYM < 1.0 * 10 ^ 9 / L (Yes: n = 40 No: n = 11), 4.HGB < 120 g/L (Yes: n = 28 No: n = 23), 5.PLT < 100*10^9/L (Yes: n = 35 No: n = 16), 6. CRP acuity 2.87 mg/L (Yes: n = 14 No: n = 37), 7.ESR ≥ 50 mm/h (Yes: n = 15 No: n = 36), 8.IL6 ≥ 7 pg/ml (Yes: n = 9 No: n = 42), 9.IgG ≥ 16 g/L (Yes: n = 43 No: n = 8), 10. C3 < 0.9 g/L (Yes: n = 37 No: n = 14), 11.C4 < 0.1 g/L (Yes: n = 43 No: n = 8), 12.RF ≥ 19 IU/ml (Yes: n = 15 No: n = 36), 13.AbSSA(52) + (Yes: n = 44 No: n = 7), 14.AbSSA(60) + (Yes: n = 45 No: n = 6), 15.AbSSB + (Yes: n = 41 No: n = 10), 16. Anti-nuclear antibody tite ≥ 1:320 (Yes: n = 937 No: n = 14). * indicates P < 0.05, which is statistically significant.) C, The concentration of hsa_circ_0045800 was different in pSS patients with complications. 1 Hypertension (Yes: n = 9 No: n = 41), 2 Coronary heart disease (Yes: n = 8 No: n = 42), 3 Hyperlipidemia (Yes: n = 25 No: n = 25), 4 Hyperuricemia (Yes: n = 11 No: n = 39), 5 Fatty liver (Yes: n = 6 No: n = 45), 6 Interstitial lung disease (Yes: n = 23 No: n = 27), 7 Hypothyroidism (Yes: n = 6 No: n = 45), 8 Chronic gastritis (Yes: n = 17 No: n = 33). * indicates P < 0.05, which is statistically significant. D, There were differences in the concentration of hsa_circ_0045800 in different disease activity stage of pSS patients. E, The concentration of hsa_circ_0045800 after treatment was decreased compared with that before treatment
We also compared the concentration of hsa_circ_0045800 in different laboratory test indicators in pSS patients. The concentration of hsa_circ_0045800 in patients with HGB < 120 g/L was higher 3.4-fold than that in patients with HGB ≥ 120 g/L (p = 0.003) (Fig. 3B, Supplement Table 1). In the conducted study, a range of experimental indicators in pSS patients, including White Blood Cell count (WBC), Neutrophil count (NEUT), Lymphocyte count (LYM), Platelet count (PLT), C-Reactive Protein (CRP), Erythrocyte Sedimentation Rate (ESR), Interleukin 6 (IL6), Immunoglobulin G (IgG), Complement C3 and C4, Rheumatoid Factor (RF), anti-SSA (52) and (60) antibodies, anti-SSB antibody, and Antinuclear Antibody titers, were divided into different level groups based on specific thresholds. The results showed that regardless of the group, there were no statistically significant differences in the concentration of hsa_circ_0045800. This indicates that the concentration of hsa_circ_0045800 is not influenced by these biochemical and immunological parameters, demonstrating its independence from these indicators (Fig. 3B, Supplement Table 3).
The concentration of hsa_circ_0045800 was decreased by 83% in pSS patients with hypothyroidism than in patients without hypothyroidism (p = 0.022) (Fig. 3C, Supplement Table 1). There was no significant difference in hsa_circ_0045800 concentration among pSS patients with hypertension, coronary heart disease, hyperlipidemia, hyperuricemia, fatty liver, pulmonary interstitial disease, and chronic gastritis (Fig. 3C, Supplement Table 4).
According to the pSS disease activity index integral criteria to judge activity degree of patient's disease, [18] ESSDAI score of 5 or more cases for activity, ESSDAI score < 5 points for non-activity. In this study, the ESSDAI score of pSS patients was 10.29 ± 5.565 points. There were 43 pSS patients in the disease active group (11.72 ± 5.378 points) and 8 pSS patients in the non-disease active group (2.75 ± 1.165 points). The concentration of hsa_circ_0045800 in the disease active group was higher 2.5-fold than that in the non-disease active group (p = 0.04) (Fig. 3D, Table 2, Supplement Table 1).
Hsa_circ_0045800 concentration after treatment in pSS patients was decreased by 80% compared with that before treatment (p = 0.037) (Fig. 3E, Table 2, Supplement Table 1).
Correlation analysis of hsa_circ_0045800 concentration with clinical features and disease activity in patients with pSS
The concentration of hsa_circ_0045800 was positively correlated with age (r = 0.328, P = 0.019), oral dryness (r = 0.331, P = 0.017). On the contrary, it was negatively correlated with HGB (r = -0.435,P = 0.001) and and hypothyroidism (r = -0.318, P = 0.023). And it had no correlation with such clinical features including sex, disease duration (month), ocular dryness, tooth damage, dry skin, fatigue, purpura, joint pain, lymph node enlargement, Raynod's phenomenon, morning stiffness, WBC, NEUT, LYM, PLT, CRP, IL-6, IgG, C3, C4, RF, AbSSA(52), AbSSA(60), AbSSB, ESSDAI, antinuclear antibody titer, combined hypertension, coronary heart disease, hyperlipidemia, hyperuricemia, fatty liver, interstitial lung disease, chronic gastritis (Table 3).
Table 3.
The association between the concentration of hsa_circ_0045800 and the clinical characteristics as well as disease activity of patients afflicted with pSS
| Index | R value | P value |
|---|---|---|
| Sex (male/female) | 0.17 | 0.228 |
| Age (years) | 0.328 | 0.019* |
| Disease duration(years) | 0.005 | 0.971 |
| Oral dryness | 0.331 | 0.017* |
| Ocular dryness | -0.077 | 0.593 |
| Tooth damage | 0.135 | 0.347 |
| Skin dryness | -0.041 | 0.774 |
| Fatigue | 0.138 | 0.335 |
| Purpura | 0.123 | 0.392 |
| Joint pain | -0.209 | 0.144 |
| Lymph node enlargement | 0.006 | 0.967 |
| Raynaud's phenomenon | -0.110 | 0.448 |
| Morning stiffness | -0.202 | 0.159 |
| WBC(*10^9/L) | -0.087 | 0.550 |
| NEUT(*10^9/L) | -0.136 | 0.348 |
| LYM(*10^9/L) | 0.039 | 0.790 |
| HGB(120 g/L) | -0.435 | 0.001* |
| PLT(100*10^9/L) | -0.143 | 0.610 |
| CRP(mg/L) | -0.338 | 0.233 |
| ESR(mm/h) | 0.606 | 0.058 |
| IL-6(pg/ml) | 0.300 | 0.432 |
| IgG(g/L) | 0.053 | 0.735 |
| C3(g/L) | 0.181 | 0.553 |
| C4(g/L) | 0.392 | 0.383 |
| RF(IU/ml) | -0.019 | 0.946 |
| Anti-Ro-52 body | -0.161 | 0.261 |
| Anti-Ro-60 body | -0.217 | 0.129 |
| Anti-SSB body | -0.170 | 0.228 |
| Antinuclear antibodies | 0.196 | 0.176 |
| ESSDAI | 0.656 | 0.000* |
| Index | r value | P value |
| Hypertension | 0.250 | 0.079 |
| Coronary heart disease | 0.177 | 0.216 |
| Hyperlipemia | -0.034 | 0.811 |
| Hyperuricemia | 0.095 | 0.508 |
| Fatty liver | 0.095 | 0.513 |
| Interstitial lung disease | -0.059 | 0.680 |
| Hypothyroidism | -0.318 | 0.023* |
| Chronic gastritis | -0.147 | 0.305 |
The concentration of hsa_circ_0045800 was positively correlated with age (r = 0.328, P = 0.019), oral dryness (r = 0.331, P = 0.017). It was negatively correlated with HGB (r = -0.435,P = 0.001) and hypothyroidism (r = -0.318, P = 0.023)
Hsa_circ_0045800 acts as a miRNA sponge for miR-1247-5P
Our investigation focused on exploring the potential miRNA targets of hsa_circ_0045800, a circular RNA known to function as a miRNA sponge. Using bioinformatics tools such as CircInteractome and circBank, we conducted an analysis to identify complementary miRNAs. Interestingly, hsa-miR-1247-5p emerged as the top candidate with a perfectly matched binding sequence to hsa_circ_0045800 (Fig. 4A). To validate the direct interaction between hsa_circ_0045800 and hsa-miR-1247-5p, we performed a dual-luciferase reporter assay in HEK293T cells. The experimental results indicated a significant decrease in relative luciferase activity when co-transfecting hsa_circ_0045800 WT with hsa-miR-1247-5p mimics compared to the control group. Conversely, co-transfection of hsa_circ_0045800 MUT with hsa-miR-1247-5p mimics did not induce any change in relative luciferase activity compared to the control group (Fig. 4B). Overall, these findings provide compelling evidence supporting the direct targeting of hsa-miR-1247-5p by hsa_circ_0045800.
Fig. 4.
Hsa_circ_0045800 functions as a sponge for miR-1247-5P. A, The binding sites between hsa_circ_0045800 and miR-1247-5P were predicted by bioinformatics analysis. B, The binding sites between hsa_circ_0045800 and miR-1247-5P were verified by a double luciferase reporter gene assay
SMAD2 is the target gene of miR-1247-5P
We utilized bioinformatics tools (targetScan and ENCORI) to search for potential target genes of hsa-miR-1247-5p. To further investigate the interaction between hsa-miR-1247-5p and SMAD2, we introduced plasmids containing SMAD2-3’ UTR-WT and SMAD2-3’ UTR-MUT into HEK293T cells. Interestingly, the luciferase activity was significantly reduced in cells co-transfected with SMAD2-3’ UTR-WT and hsa-miR-1247-5p mimics compared to the control group (Fig. 5).
Fig. 5.
SMAD2 is the target gene of miR-1247-5P. A, The binding sites between SMAD2 and miR-1247-5P were predicted by bioinformatics analysis. B, The binding sites between SMAD2 and miR-1247-5P was verified by double luciferase reporter gene assay
Discussion
In the progression of various autoimmune disorders, circRNAs exert their biological influence through a variety of mechanisms [8]. Mounting evidence has demonstrated that circRNAs may play a pivotal role in governing gene expression and transcription by functioning as microRNA (miRNA) reservoirs, impacting cell viability and proliferation through interaction with RNA binding proteins (RBPs), and enhancing mRNA stability by forming RNA–protein complex duplex structures [11, 14, 15]. In systemic lupus erythematosus (SLE), the expression level of circLOC101928570 experiences significant downregulation, which exhibits correlation with the systemic lupus erythematosus disease activity index. Functioning as a molecular reservoir for miR-150-5p, circLOC101928570 alleviates the inhibitory effect of its target gene, c-myb [19]. Moreover, Circ_0088194 stimulates the invasion and migration of fibroblast-like synovial cells in rheumatoid arthritis via the miR-766-3p/MMP2 axis [20]. Nonetheless, only a limited number of studies have elucidated the role of circRNAs in primary Sjögren's syndrome (pSS). In our present study, we initially identified a pivotal circRNA (circURE2O, circBase ID: hsa_circ_0045800) in pSS. The principal findings indicated that it had substantial elevated concentration in peripheral blood mononuclear cells of pSS patients, which closely correlate with multiple clinical features and disease activity.
We conducted a thorough analysis of the association between hsa_circ_0045800 and the clinical characteristics of primary Sjögren's syndrome (pSS). The concentration of hsa_circ_0045800 in pSS patients with activity stage was notably higher than that with non-activity stage, displaying a positive correlation with the European League Against Rheumatism Sjögren's Syndrome Disease Activity Index (ESSDAI). Notably, the concentration of hsa_circ_0045800 decreased significantly after treatment. Additionally, the concentration of hsa_circ_0045800 exhibited a decline in pSS patients with hypothyroidism, demonstrating a negative correlation with this condition. Interestingly, the concentration of hsa_circ_0045800 was higher in patients with hemoglobin levels below 120 g/L, displaying a negative correlation with hemoglobin (HGB). This study revealed that has_circ_0045800 possesses high sensitivity and specificity, suggesting its potential as a valuable biomarker associated with the diagnosis of pSS. This discovery opens up new possibilities for early screening and differential diagnosis of pSS. Future investigations could explore the combination of hsa_circ_0045800 with established pSS biomarkers to enhance diagnostic accuracy and reliability. The parental gene of hsa_circ_0045800, UBE2O (ubiquitin binding enzyme E2O), operates as an E3-independent E2 (i.e., E2/E3 heterosynthase), enabling direct ubiquitination of various substrates [21]. GomeZ-Martin et al. demonstrated the significant upregulation of the ubiquitination signaling pathway in pSS patients [22]. UBE2O plays a vital role in diverse cellular processes, encompassing cell cycle regulation, protein quality control, DNA damage repair, cellular development, and differentiation, among other biological processes [23–27]. This study further explored the molecular mechanism of hsa_circ_0045800 in pSS, revealing its capability to promote pSS progression by targeting miR-1247-5p and SMAD2.
MicroRNAs (miRNAs) are diminutive noncoding, unpaired RNAs that govern gene expression and impact numerous cellular processes such as proliferation, differentiation, and apoptosis [28, 29]. MiR-1247 consists of miR-1247-5p and miR-1247-3p [30, 31]. Studies have revealed that miR-1247 may act as a key regulator of cartilage function, with substantial effects on cartilage matrix production from human chondrocytes [30]. It directly targets the cartilage master regulator gene SOX9 through a deeply conserved region within its coding sequence [30]. Jennifer Liang et al. demonstrated that miR-1247 functions as an innovative tumor suppressor by inhibiting MYCBP2 in methylated colon cancer. The role of miR-1247 in pSS remains unknown [31]. Using database analysis, we identified binding sites for hsa_circ_0045800 and miR-1247-5p, which were subsequently confirmed by luciferase assay. This discovery suggests that hsa_circ_0045800 may act as a molecular reservoir for miR-1247-5p, regulating its downstream target genes involved in the progression of pSS. Furthermore, using luciferase reporter assays, we investigated the potential binding of miR-1247-5p to SMAD2, revealing a greatly conserved region within the encoding sequence of SMAD2 as the binding site, rather than its 3’ UTR.
Recognized as a member of the SMAD family, SMAD2 functions as an intracellular signal transducer and downstream transcriptional regulator of transforming growth factor-β (TGF-β) [32, 33]. The involvement of SMAD2 spans fetal development, inflammatory responses, tissue differentiation, and even tumorigenesis. Transforming growth factor (TGF)-β, a multifaceted cytokine, governs cell growth and differentiation, extracellular matrix deposition, fibrosis, and installation [34]. TGF-β1, specifically, plays a pivotal role in initiating fibrosis, commonly observed during chronic stages of inflammatory diseases, which detrimentally affect normal organ function [35, 36]. The biological effects of TGF-β1 signaling are mediated through the TGF-β/SMAD/Snail pathway, thereby exerting a significant pathogenic influence on various fibrotic disorders [37]. However, its implications in Sjögren's syndrome (SS), a chronic autoimmune disease, have received limited investigation. Prior studies indicate that circRNAs can modulate the TGF-β/SMAD pathway in breast cancer (BCa) [38], with circRIP2 notably expediting BCa progression via the miR-1305/TGF-β2/smad3 pathway [35, 37, 38]. In this study, a compelling finding emerged wherein hsa_circ_0045800 was found to regulate SMAD2 by suppressing miR-1247-5p, thereby further substantiating the pivotal role of circRNAs in modulating the activation of the TGF-β/SMAD pathway.
However, certain limitations were also encountered. For instance, it is possible that hsa_circ_0045800 targets additional miRNAs and modulates alternative downstream pathways, which necessitates further exploration of its underlying mechanisms. Noncoding RNAs, such as micro-RNAs, exhibit minimal specificity towards a single disease, posing challenges in utilizing a solitary molecule for disease diagnosis or activity assessment. Instead, circRNAs offer potential as an adjunctive diagnostic tool, distinct from conventional laboratory serological markers and inflammation-related parameters, thereby warranting consideration.
In conclusion, we have unveiled previously unknown circRNA, hsa_circ_0045800, in peripheral blood mononuclear cells of pSS. Peripheral blood mononuclear cells are a heterogeneous group of cells, which play a key role in the immune response and are directly involved in the pathogenesis of pSS. Mechanistically, hsa_circ_0045800 may be involved in the development of pSS through miR-1247-5p/SMAD2. These findings hold promise for clinical application, underscoring the need for comprehensive investigation into the biological roles and molecular mechanisms of circRNAs.
Supplementary Information
Below is the link to the electronic supplementary material.
Authors' contributions
Hong Zhu, Yi Wang and Xiaoyu Zhang contributed to edit the manuscript. Ge Wang,Yitong Ling, Jinhai Tian, Yan Zhou, Rong Zhu, Rui Wang, Ruixin Wang and Peng Jian collected and analyzed data. Xiaoyu Zhang,Hong Zhu and Wenhui Zhang designed and revised the paper. All authors approved and agreed to submit the manuscript.
Funding
The study was supported by nature science foundation of Ningxia province (2022AAC02066).
Data availability
The dataset analyzed in this study is available through request from the corresponding author at nxzhuh@126.com.
Declarations
Ethics approval
This study was approved by the Medical Ethics Committee of Ningxia Medical University General Hospital (Ethics No. 2018–099 2020–313).
Conflict of interest
None of the authors had a conflict of interest about the study.
Consent to participate
Informed consent was obtained from all individual participants included in the study.
Consent for publication
The study was published under the condition of the patients and their family members.
Footnotes
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Hong Zhu and Yi Wang contributed equally to this work.
Contributor Information
Wenhui Zhang, Email: Wenhuicomeon@163.com.
Xiaoyu Zhang, Email: xiaoyu1935@163.com.
References
- 1.Parisis D et al (2020) Current state of knowledge on primary Sjogren’s syndrome, an autoimmune exocrinopathy. J Clin Med 9(7):2299 [DOI] [PMC free article] [PubMed]
- 2.Wang J, Zhou L, Liu B (2020) Update on disease pathogenesis, diagnosis, and management of primary Sjogren’s syndrome. Int J Rheum Dis 23(6):723–727 10.1111/1756-185X.13839 [DOI] [PubMed] [Google Scholar]
- 3.Rischmueller M, Tieu J, Lester S (2016) Primary Sjogren’s syndrome. Best Pract Res Clin Rheumatol 30(1):189–220 10.1016/j.berh.2016.04.003 [DOI] [PubMed] [Google Scholar]
- 4.Lawrence RC et al (2008) Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II Arthritis Rheum 58(1):26–35 10.1002/art.23176 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Baldini C et al (2014) Primary Sjogren’s syndrome as a multi-organ disease: impact of the serological profile on the clinical presentation of the disease in a large cohort of Italian patients. Rheumatology (Oxford) 53(5):839–844 10.1093/rheumatology/ket427 [DOI] [PubMed] [Google Scholar]
- 6.Delaleu N, et al. (2008) New concepts in the pathogenesis of Sjogren's syndrome. Rheum Dis Clin North Am 34(4) 833–45, vii [DOI] [PubMed]
- 7.Chen LL, Yang L (2015) Regulation of circRNA biogenesis. RNA Biol 12(4):381–388 10.1080/15476286.2015.1020271 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Zhang Z, Yang T, Xiao J (2018) Circular RNAs: Promising Biomarkers for Human Diseases. EBioMedicine 34:267–274 10.1016/j.ebiom.2018.07.036 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Ji P et al (2019) Expanded Expression Landscape and Prioritization of Circular RNAs in Mammals. Cell Rep 26(12):3444-3460.e5 10.1016/j.celrep.2019.02.078 [DOI] [PubMed] [Google Scholar]
- 10.Meng S et al (2017) CircRNA: functions and properties of a novel potential biomarker for cancer. Mol Cancer 16(1):94 10.1186/s12943-017-0663-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Zhou WY et al (2020) Circular RNA: metabolism, functions and interactions with proteins. Mol Cancer 19(1):172 10.1186/s12943-020-01286-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Shi Y, Jia X, Xu J (2020) The new function of circRNA: translation. Clin Transl Oncol 22(12):2162–2169 10.1007/s12094-020-02371-1 [DOI] [PubMed] [Google Scholar]
- 13.Chen L, Shan G (2021) CircRNA in cancer: Fundamental mechanism and clinical potential. Cancer Lett 505:49–57 10.1016/j.canlet.2021.02.004 [DOI] [PubMed] [Google Scholar]
- 14.Altesha MA et al (2019) Circular RNA in cardiovascular disease. J Cell Physiol 234(5):5588–5600 10.1002/jcp.27384 [DOI] [PubMed] [Google Scholar]
- 15.Ma N, Zhang W, Wan J (2020) Research Progress on circRNA in Nervous System Diseases. Curr Alzheimer Res 17(8):687–697 10.2174/1567205017666201111114928 [DOI] [PubMed] [Google Scholar]
- 16.Zhou Z et al (2019) Roles of circular RNAs in immune regulation and autoimmune diseases. Cell Death Dis 10(7):503 10.1038/s41419-019-1744-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Ji J et al (2022) Hsa_circ_0008301 as a potential biomarker of disease activity for primary Sjogren’s syndrome: Increased expression in peripheral blood of patients with primary Sjogren’s syndrome. Int Immunopharmacol 112:109231 10.1016/j.intimp.2022.109231 [DOI] [PubMed] [Google Scholar]
- 18.Seror R et al (2015) EULAR Sjogren’s syndrome disease activity index (ESSDAI): a user guide. RMD Open 1(1):e000022 10.1136/rmdopen-2014-000022 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Zhao X et al (2022) Circular RNA circLOC101928570 suppresses systemic lupus erythematosus progression by targeting the miR-150-5p/c-myb axis. J Transl Med 20(1):547 10.1186/s12967-022-03748-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Cai Y et al (2021) Circ_0088194 Promotes the Invasion and Migration of Rheumatoid Arthritis Fibroblast-Like Synoviocytes via the miR-766-3p/MMP2 Axis. Front Immunol 12:628654 10.3389/fimmu.2021.628654 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Ullah K et al (2019) Diverse roles of the E2/E3 hybrid enzyme UBE2O in the regulation of protein ubiquitination, cellular functions, and disease onset. FEBS J 286(11):2018–2034 10.1111/febs.14708 [DOI] [PubMed] [Google Scholar]
- 22.Gomez-Martin D, Diaz-Zamudio M, Alcocer-Varela J (2008) Ubiquitination system and autoimmunity: the bridge towards the modulation of the immune response. Autoimmun Rev 7(4):284–290 10.1016/j.autrev.2007.11.026 [DOI] [PubMed] [Google Scholar]
- 23.Chen X et al (2020) UBE2O Promotes Progression and Epithelial-Mesenchymal Transition in Head and Neck Squamous Cell Carcinoma. Onco Targets Ther 13:6191–6202 10.2147/OTT.S253861 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Huang Y et al (2021) UBE2O targets Mxi1 for ubiquitination and degradation to promote lung cancer progression and radioresistance. Cell Death Differ 28(2):671–684 10.1038/s41418-020-00616-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Shi Z et al (2021) UBE2O promotes hepatocellular carcinoma cell proliferation and invasion by regulating the AMPKalpha2/mTOR pathway. Int J Med Sci 18(16):3749–3758 10.7150/ijms.63220 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Cen X et al (2022) UBE2O ubiquitinates PTRF/CAVIN1 and inhibits the secretion of exosome-related PTRF/CAVIN1. Cell Commun Signal 20(1):191 10.1186/s12964-022-00996-z [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Yanagitani K, Juszkiewicz S, Hegde RS (2017) UBE2O is a quality control factor for orphans of multiprotein complexes. Science 357(6350):472–475 10.1126/science.aan0178 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Vienberg S et al (2017) MicroRNAs in metabolism. Acta Physiol (Oxf) 219(2):346–361 10.1111/apha.12681 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Naqvi AR, Sarwat M (2022) MicroRNAs and immunity. Semin Cell Dev Biol 124:1–2 10.1016/j.semcdb.2021.10.007 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Dreval K et al (2017) miR-1247 blocks SOX9-mediated regeneration in alcohol- and fibrosis-associated acute kidney injury in mice. Toxicology 384:40–49 10.1016/j.tox.2017.03.004 [DOI] [PubMed] [Google Scholar]
- 31.Liang J et al (2018) Epigenetically regulated miR-1247 functions as a novel tumour suppressor via MYCBP2 in methylator colon cancers. Br J Cancer 119(10):1267–1277 10.1038/s41416-018-0249-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Fleming NI et al (2013) SMAD2, SMAD3 and SMAD4 mutations in colorectal cancer. Cancer Res 73(2):725–735 10.1158/0008-5472.CAN-12-2706 [DOI] [PubMed] [Google Scholar]
- 33.Braganca J (2018) SMAD2/3, versatile molecular tools for cellular engineering. Stem Cell Investig 5:24 10.21037/sci.2018.07.05 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Zhou WJ et al (2020) NEAT1/miR-200b-3p/SMAD2 axis promotes progression of melanoma. Aging (Albany NY) 12(22):22759–22775 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Massague J, Blain SW, Lo RS (2000) TGFbeta signaling in growth control, cancer, and heritable disorders. Cell 103(2):295–309 10.1016/S0092-8674(00)00121-5 [DOI] [PubMed] [Google Scholar]
- 36.Fortunel NO, Hatzfeld A, Hatzfeld JA (2000) Transforming growth factor-beta: pleiotropic role in the regulation of hematopoiesis. Blood 96(6):2022–2036 10.1182/blood.V96.6.2022 [DOI] [PubMed] [Google Scholar]
- 37.Su Y et al (2020) circRIP2 accelerates bladder cancer progression via miR-1305/Tgf-beta2/smad3 pathway. Mol Cancer 19(1):23 10.1186/s12943-019-1129-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Zhang Z et al (2022) Circ_0002623 promotes bladder cancer progression by regulating the miR-1276/SMAD2 axis. Cancer Sci 113(4):1250–1263 10.1111/cas.15274 [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
The dataset analyzed in this study is available through request from the corresponding author at nxzhuh@126.com.